PHASE II STUDY OF CLADRIBINE AND LOW-DOSE ARAC ALTERNATING WITH DECITABINE IN OLDER PATIENTS WITH AML

被引：0
|
作者：
Kadia, T. [1 ]
Cortes, J. [1 ]
Borthakur, G. [1 ]
Jabbour, E. [1 ]
Daver, N. [1 ]
Pemmaraju, N. [1 ]
Verstovsek, S. [1 ]
Burger, J. [1 ]
Ferrajoli, A. [1 ]
Wierda, W. [1 ]
Konopleva, M. [1 ]
DiNardo, C. [1 ]
Jain, N. [1 ]
Brandt, M. [1 ]
Tuttle, C. [1 ]
Wang, X. [1 ]
Ravandi, F. [1 ]
Garcia-Manero, G. [1 ]
Kantarjian, H. [1 ]
机构：
[1] Univ Texas MD Anderson Canc Ctr, Leukemia, Houston, TX 77030 USA
来源：
HAEMATOLOGICA | 2016年 / 101卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
P187
引用
收藏
页码：42 / 42
页数：1
相关论文
共 50 条
  • [21] Continued low-dose decitabine (DAC) is an active first-line treatment.: In all cytogenetic subgroups of older AML patients:: Results of the FR00331 multicenter phase II study
    Luebbert, Michael
    Rueter, Bjorn
    Claus, Rainer
    Schmid, Mathias
    Germing, Ulrich
    Eimeracher, Hartmut
    Ganser, Arnold
    Platzbecker, Uwe
    Galm, Oliver
    Brugger, Wolfram
    Heil, Gerhard
    Wijermans, Pierre W.
    Pfeifer, Dietmar
    Schmoor, Claudia
    Doehner, Hartmut
    BLOOD, 2007, 110 (11) : 95A - 95A
  • [22] Phase II study of low-dose decitabine in combination with imatinib mesylate in patients with accelerated or myeloid blastic phase of chronic myelogenous leukemia
    Oki, Yasuhiro
    Kantarjian, Hagop M.
    Gharibyan, Vazganush
    Jones, Dan
    O'Brien, Susan
    Verstovsek, Srdan
    Cortes, Jorge
    Morris, Gail M.
    Garcia-Manero, Guillermo
    Issa, Jean-Pierre J.
    CANCER, 2007, 109 (05) : 899 - 906
  • [23] Venetoclax Added to Cladribine (CLAD) plus Low Dose AraC (LDAC) Alternating with Azacitidine (AZA) Is Highly Active As Frontline Therapy in Older Patients with Newly Diagnosed Acute Myeloid Leukemia in a Phase 2 Study
    Reville, Patrick K.
    Kantarjian, Hagop
    Borthakur, Gautam
    Pemmaraju, Naveen
    Daver, Naval
    DiNardo, Courtney D.
    Sasaki, Koji
    Short, Nicholas
    Issa, Ghayas C.
    Ohanian, Maro
    Jabbour, Elias
    Montalban-Bravo, Guillermo
    Maiti, Abhishek
    Jain, Nitin
    Ferrajoli, Alessandra
    Bhalla, Kapil N.
    Takahashi, Koichi
    Rausch, Caitlin R.
    Hammond, Danielle
    Malla, Rashmi
    Quagliato, Kelly
    Brandt, Mark
    Popat, Uday R.
    Konopleva, Marina
    Garcia-Manero, Guillermo
    Ravandi, Farhad
    Kadia, Tapan M.
    BLOOD, 2022, 140 : 9041 - 9043
  • [24] Phase II Study of Venetoclax Added to Cladribine plus Low Dose AraC (LDAC) Alternating with 5-Azacytidine Demonstrates High Rates of Minimal Residual Disease (MRD) Negative Complete Remissions (CR) and Excellent Tolerability in Older Patients with Newly Diagnosed Acute Myeloid Leukemia (AML)
    Kadia, Tapan M.
    Borthakur, Gautam
    Pemmaraju, Naveen
    Daver, Naval
    DiNardo, Courtney D.
    Sasaki, Koji
    Issa, Ghayas C.
    Ohanian, Maro
    Bravo, Guillermo Montalban
    Short, Nicholas J.
    Jain, Nitin
    Ferrajoli, Alessandra
    Bhalla, Kapil N.
    Jabbour, Elias
    Kanagal-Shamanna, Rashmi
    Takahashi, Koichi
    Malla, Rashmi
    Marek, Kelly
    Brandt, Mark
    Popat, Uday R.
    Andreeff, Michael
    Cortes, Jorge E.
    Garcia-Manero, Guillermo
    Konopleva, Marina
    Ravandi, Farhad
    Kantarjian, Hagop M.
    BLOOD, 2020, 136
  • [25] Genomic impact of transient low-dose decitabine treatment on primary AML cells
    Klco, Jeffery M.
    Spencer, David H.
    Lamprecht, Tamara L.
    Sarkaria, Shawn M.
    Wylie, Todd
    Magrini, Vincent
    Hundal, Jasreet
    Walker, Jason
    Varghese, Nobish
    Erdmann-Gilmore, Petra
    Lichti, Cheryl F.
    Meyer, Matthew R.
    Townsend, R. Reid
    Wilson, Richard K.
    Mardis, Elaine R.
    Ley, Timothy J.
    BLOOD, 2013, 121 (09) : 1633 - 1643
  • [26] A Metabolically Optimized, Noncytotoxic Low-Dose Weekly Decitabine/Venetoclax in MDS and AML
    Levitz, David
    Saunthararajah, Yogen
    Fedorov, Kateryna
    Shapiro, Lauren C.
    Mantzaris, Ioannis
    Shastri, Aditi
    Kornblum, Noah
    Sica, R. Alejandro
    Shah, Nishi
    Konopleva, Marina
    Gritsman, Kira
    Braunschweig, Ira
    Cooper, Dennis L.
    Pradhan, Kith
    Verma, Amit
    Feldman, Eric J.
    Finger, Mendel Gold
    CLINICAL CANCER RESEARCH, 2023, 29 (15) : 2774 - 2780
  • [27] LOW-DOSE ARA-C AS AN ALTERNATIVE THERAPY FOR OLDER PATIENTS WITH AML
    HEYLL, A
    AUL, C
    HEYLL, U
    FISCHER, JT
    SCHNEIDER, W
    BLUT, 1985, 51 (03): : 163 - 163
  • [28] Clofarabine Plus Low-Dose Cytarabine Induction Followed by Consolidation with Clofarabine Plus Low-Dose Cytarabine Alternating with Decitabine as Frontline Therapy for Patients (pts) with Acute Myeloid Leukemia (AML) ≥ 60 Years (yrs)
    Parikh, Sameer A.
    Kantarjian, Hagop
    Garcia-Manero, Guillermo
    Jabbour, Elias
    Kadia, Tapan
    Ravandi, Farhad
    Ferrajoli, Alessandra
    Estrov, Zeev
    Feliu, Jenny
    Faderl, Stefan
    BLOOD, 2009, 114 (22) : 813 - 813
  • [29] Intergroup study in elderly patients with AML to compare complete remission rate and overall survival after intermediate-dose or low-dose AraC.
    Lange, T.
    Niederwieser, D.
    Hoffmann, V.
    Pfirrmann, M.
    Maschmeyer, G.
    Fischer, T.
    Herold, M.
    Sayer, H. G.
    Junghanss, C.
    Krahl, R.
    Al-Ali, H. K.
    Poenisch, W.
    Vucinic, V.
    Doelken, G.
    Sauerland, M. C.
    Heinecke, A.
    Hoelzer, D.
    Hehlmann, R.
    Berdel, W. E.
    Buchner, T.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [30] Cladribine, Low-Dose Cytarabine (LDAC), and Venetoclax (VEN) in Older/Unfit Acute Myeloid Leukemia (AML) Patients: A Single-Institution Experience
    Yohannan, Binoy
    Khan, Hina
    Cervoni-Curet, Frances
    Rios, Adan
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S267 - S267
12345